AAV Biodistribution Analysis
Understanding the biodistribution of AAV vectors is essential when developing novel AAV vectors, especially those use novel AAV capsids, promoters, or enhancers. AAV Biodistribution studies provide comprehensive insights into how and where the vector travels and transduces tissues following administration. This information is crucial for assessing targeting specificity, off-target effects, and potential safety concerns. For new capsids engineered to improve tissue tropism or evade the immune system, thorough biodistribution analysis helps validate their intended performance in vivo. It enables researchers to confirm efficient delivery to target tissues while minimizing unwanted spread to non-target organs. Moreover, biodistribution data support dose optimization and inform regulatory submissions by demonstrating vector behavior in relevant animal models. In sum, robust AAV biodistribution profiling is a cornerstone of successful novel capsid development, ensuring both efficacy and safety in preclinical and clinical applications.
AAV Biodistribution Analysis at AAVnerGene
Whether you are working with a handful of capsids or a large number of capsids, AAVnerGene provides the tools and expertise to optimize your AAV biodistribution evaluation processes. Contact us today to learn more about our services and how we can support your gene therapy research!
- For ≤10 AAV Vectors:
- Service: Individual testing with high-resolution data.
- Output: Detailed analysis at the DNA, RNA, and protein levels.
- Methods: qPCR for AAV genome and RNA expression, reporter gene functional tests.
- Use Case: In-depth characterization of a small number of highly promising candidates.
- For Tens of AAV Vectors:
- Service: Use AAV barcode technology for batch analysis.
- Output: Efficient barcode-based analysis with insights at the mRNA and DNA levels.
- Methods: NGS for barcoded DNA and RNA, scRNA-AAVseq for single-cell level analysis.
- Use Case: Screening a moderate number of capsids with balanced depth and throughput.
- For Hundreds of AAV Vectors:
- Service: Use custom AAV Libraries for large batch analysis.
- Output: Scalable, high-throughput screening using large libraries.
- Methods: NGS for barcoded DNA and RNA, scRNA-AAVseq for single-cell analysis.
- Use Case: Rapid identification of top-performing capsids from a highly diverse library.
Individual AAV Biodistribution Analysis
AAVnerGene offers Individual AAV Biodistribution Analysis for researchers who need detailed, high-resolution evaluation of a small number of capsid variants. This service is ideal for in-depth characterization and validation of top candidates identified from larger screens or for targeted optimization projects.
High-Resolution Data: Comprehensive analysis at the DNA, RNA, and protein levels to assess capsid performance.
Biodistribution of AAV Vectors: Tailored to your specific needs for whether evaluating tropism, transduction efficiency. Utilizes techniques such as qPCR for AAV genome and RNA expression quantification, and reporter gene functional assays (e.g., fluorescence or luminescence) to measure transduction efficiency.
Capable of analyzing any tissue types. Compatible with all tissue types for comprehensive analysis; Collect any tissue sample for precise qPCR analysis; Co-immunostaining available with tissue-specific biomarkers for enhanced detection.
Using AAV Barcode Technology to Analyze AAVs Simultaneously
AAV barcode technology allows simultaneous analysis of multiple AAV vectors in a single experiment, significantly boosting throughput and efficiency. By uniquely labeling each AAV capsid variant or promoter/enhancer with a distinct DNA barcode, researchers can pool dozens—or even hundreds—of vectors for combined administration.
After in vitro or in vivo delivery, the barcode sequences are recovered from target tissues or cells and quantified using next-generation sequencing (NGS). This approach allows precise tracking of each vector’s biodistribution, transduction efficiency, and tissue tropism in a single comprehensive assay.
The multiplexed nature of AAV barcode analysis reduces cost, time, and animal usage compared to traditional one-by-one vector testing. It also enables rapid screening and identification of the most promising capsid variants for further development.
Overall, AAV barcode technology is a powerful tool for accelerating capsid engineering, optimizing vector libraries, and advancing gene therapy research with unprecedented scale and precision.
Custom AAV Barcode Library for Large Number of AAVs
Based on our AAV Barcode technology, customers can choose their own AAV capsids, promoters, reporters, and other elements to make their own AAV barcode libraries. AAVnerGene also offers comprehensive construction and production services for AAV Capsid Barcode Libraries, AAV Promoter Libraries, and AAV Enhancer Libraries.
- Capsid Selection
- Select a diverse set of capsids representing different serotypes, tropisms, and transduction efficiencies.
- Include well-characterized AAV variants (e.g., AAV2, AAV9) and engineered capsids with modified properties.
- Consider tissue specificity, receptor binding, and immunogenicity for optimal targeting.
- Promoter/enhancer Selection
- Select a diverse set of promoters/enhancers you want to compare.
- Choose a cell type-specific or ubiquitous promoter as a control.
- Ensure appropriate expression levels and duration for your experimental needs.
- Reporter System
- Use a detectable reporter gene (e.g., GFP, mCherry, luciferase, or β-galactosidase) to evaluate transduction efficiency.
- Select reporters compatible with imaging, flow cytometry, or enzymatic assays.
- Barcode Strategy
- Integrate unique DNA barcodes (in non-coding regions) for capsid variant tracking.
- Optimize barcode length, diversity, and sequence composition to ensure uniqueness and avoid recombination.
- Ensure compatibility with NGS (barcode-seq) or single-cell analysis (scRNA-AAVseq).
- Production Scale Determination:
- Library size (number of variants)
- In vivo requirements (animal weight, dose per variant)
- Downstream applications (screening, biodistribution studies)
- Library Production
- Individual purification → Higher consistency and accuracy.
- Pooled purification → Cost-effective for high-throughput workflows.
- In Vivo Screening
- Select appropriate animal models (e.g., mice, NHP) for target tissue tropism studies.
- Harvest and analyze relevant tissues (e.g., liver, brain, muscle).
- Analysis Methods
- DNA-level: Barcode-seq for capsid biodistribution.
- RNA-level: scRNA-AAVseq for single-cell tropism and expression profiling.
Example: AAV Capsid Barcode Kit-Common
The AAV Capsid Barcode Kit-CAG-EGFP was systematically injected into C57B6 mice, and all tissues were collected two weeks post-injection. DNA and RNA were extracted from the tissues to prepare NGS libraries. The data reflects the enrichment fold of barcodes (BCs) in each tissue relative to the input viruses, as determined through NGS analysis.
AAV tissue tropisms in mice Results:
- Overall RNA: AAV9, AAVrh.10.
- Overall DNA: AAV-DJ, AAVrh.74.
- Liver: RNA: AAV9>AAVrh.10>AAV8; DNA, AAV-DJ>AAVrh.74>AAV8
- Lung: RNA: AAV9>AAV11>AAVrh.10; DNA, AAV11>AAVrh.74=AAV8=AAVrh.10
- Brain(BBB): RNA, AAV9>AAVrh.10>AAV8; DNA, AAV9>AAVrh.10=AAV8=AAV11
- Heart RNA: AAVDJ>AAV9>AAVrh.10; DNA, AAV11>AAVrh.74>AAV-DJ
- Kidney RNA: AAV9>AAVrh.10>AAV8; DNA, AAV-DJ>AAV8>AAV3B
AAV Evaluation Models
To assess capsid performance in complex biological systems, we screen AAV capsids using a range of animal models, including:
Small Animals: Mice and rats for initial in vivo testing and proof-of-concept studies.
Non-Human Primates (NHPs): For translational studies and immune response evaluation.
Large Animals: Pigs, dogs, and other large animals to model human physiology and disease more closely.
AAV vector development, back to the future. Mol Ther. 2025 May 7;33(5):1903-1936.
Animal models play a critical role in screening AAVs designed to target specific tissues. Recent studies have highlighted a key finding: AAVs can perform differently across species and animal strains, underscoring the importance of cross-species testing [Tabebordba et al., 2021; Gonzalez et al., 2022]. For instance, AAV-PHP.B displayed the ability to cross the blood-brain barrier (BBB) in specific mouse strains but not in non-human primates (NHPs) [Hordeaux et al., 2018; Matsuzaki et al., 2019]. To identify variants that are more likely to be effective in humans, it is essential to conduct variant screening in a range of animal models and human-based systems, ensuring the selection of AAVs with translatable performance. The directed evolution of a random peptide insertion library of AAV9 (VR-VIII) led to the development of the AAV-PHP family, with AAV-PHP.B showing significantly enhanced BBB-crossing capabilities in mice. Subsequent engineering of AAV-PHP.B resulted in the creation of AAV-PHP.eB, which retains the same peptide insertion but incorporates additional flanking substitutions. AAV-PHP.eB demonstrated efficient central nervous system (CNS) transduction in mice, achieving 55–76% neuron transduction depending on the region—more than 2.5 times that of AAV-PHP.B. Further modifications led to liver de-targeted variants of AAV-PHP.eB, including AAV.CAP-B10 and AAV.CAP-B22. AAV.CAP-B10 maintained CNS targeting in mice while exhibiting reduced transduction of peripheral organs and a 50-fold decrease in liver tropism compared to AAV-PHP.eB, and over 100-fold compared to AAV9. This variant showed specific neuronal targeting within the CNS, with fewer transduced astrocytes and oligodendrocytes compared to AAV-PHP.eB. Notably, AAV.CAP-B10 achieved broad and robust transgene expression in the CNS of adult marmosets, with a 4-fold increase in CNS transduction over AAV9 and a 17-fold reduction in liver expression compared to AAV9. However, when administered as a pool in infant rhesus macaques, AAV.CAP-B10 produced only slightly higher CNS enrichment compared to AAV9. AAV.CAP-B22, another variant, demonstrated even higher CNS transduction in marmosets, achieving a 12-fold increase compared to AAV9. However, it also showed greater astrocyte transduction than both AAV9 and AAV.CAP-B10. While AAV.CAP-B22 showed similar liver tropism to AAV9, it did not effectively translate in newborn rhesus macaques.
AAV vector development, back to the future. Mol Ther. 2025 May 7;33(5):1903-1936.